Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Aktuell zu Ihren Aktien: YOC (Boersengefluester) +++ YOC Aktie -3,36%

Foren & Soziale Netzwerke zur GERON Aktie

 >GERON Aktienkurs 
1.3315 EUR    +0.1%    (Tradegate)
Ask: 1.3435 EUR / 2233 Stück
Bid: 1.3305 EUR / 2256 Stück
Tagesumsatz: 200 Stück
Realtime Kurs von 8 bis 22 Uhr!
GERON Aktie über LYNX handeln
>GERON Performance
1 Woche: +3,0%
1 Monat: +2,3%
3 Monate: -17,4%
6 Monate: -59,5%
1 Jahr: -68,9%
laufendes Jahr: -58,9%
>GERON Aktie
Name:  GERON CORP. (DEL.) DL-001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US3741631036 / 902213
Symbol/ Ticker:  GON (Frankfurt) / GERN (NASDAQ)
Kürzel:  FRA:GON, ETR:GON, GON:GR, NASDAQ:GERN
Index:  -
Webseite:  https://www.geron.com/
Marktkapitalisierung:  857.64 Mio. EUR
Umsatz:  100.74 Mio. EUR
EBITDA:  -115.86 Mio. EUR
Gewinn je Aktie:  -0.156 EUR
Schulden:  105.5 Mio. EUR
Liquide Mittel:  343.82 Mio. EUR
Umsatz-/ Gewinnwachstum:  12% / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  9.15 / 3.82 / -
Gewinnm./ Eigenkapitalr.:  -119.54% / -45.35%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  GERON
Letzte Datenerhebung:  25.06.25
>GERON Eigentümer
Aktien: 636.92 Mio. St.
f.h. Aktien: 537.81 Mio. St.
Insider Eigner: 0.09%
Instit. Eigner: 81.23%
>GERON Peer Group

 
03.05.25 - 15:21
BetaTiger89: buy Geron Corp. (Sharewise)
 
Kursziel: -
12.03.25 - 15:03
Needham___Company_LL: buy Geron Corp. (Sharewise)
 
Kursziel: 4.583 €
27.02.25 - 17:03
Stifel_Nicolaus: buy Geron Corp. (Sharewise)
 
Kursziel: 3.8396 €
13.01.25 - 17:03
Needham___Company_LL: buy Geron Corp. (Sharewise)
 
Kursziel: 6.8628 €
24.12.24 - 22:36
DerAlmanach100000: buy Geron Corp. (Sharewise)
 
Kursziel: 3.0 €
13.12.24 - 15:33
Needham___Company_LL: buy Geron Corp. (Sharewise)
 
Kursziel: 5.7138 €
01.11.24 - 14:54
AI_Picker: buy Geron Corp. (Sharewise)
 
Kursziel: 5.5 €
26.07.24 - 22:18
Needham___Company_LL: buy Geron Corp. (Sharewise)
 
Kursziel: 5.5248 €
10.06.24 - 17:18
Barclays_PLC: buy Geron Corp. (Sharewise)
 
Kursziel: 8.379 €
10.06.24 - 15:18
Stifel_Nicolaus: buy Geron Corp. (Sharewise)
 
Kursziel: 6.5114 €
09.06.24 - 17:39
mixitrader: buy Geron Corp. (Sharewise)
 
Kursziel: 8.0 €
07.06.24 - 16:18
Needham___Company_LL: buy Geron Corp. (Sharewise)
 
Kursziel: 5.547 €
07.06.24 - 15:18
Wedbush: buy Geron Corp. (Sharewise)
 
Kursziel: 6.4638 €
07.06.24 - 13:57
Vassago1: sell Geron Corp. (Sharewise)
 
Kursziel: -
03.06.24 - 18:45
GERN - PDUFA Data Release on 16/06/2024 (TradingView)
 
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology. Recent Activity Blockbuys: See the screenshot in the chart. Expecting: A pre run-up into the data release on 16/06/2024. Key Technical Levels Breakout Zone: $3.70 - $4.00 (Very strong resistance) Resistance Points: $4.30 $4.60 Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains. Trading Strategy Take Profit (TP): Target $5.00 to capitalize on the anticipated pri
03.06.24 - 18:33
GERN - PDUFA Data Realease on 16/06/2024 (TradingView)
 
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology. Recent Activity Blockbuys: See the screenshot in the chart. Expecting: A pre run-up into the data release on 16/06/2024. Key Technical Levels Breakout Zone: $3.70 - $4.00 (Very strong resistance) Resistance Points: $4.30 $4.60 Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains. Trading Strategy Take Profit (TP): Target $5.00 to capitalize on the anticipated pri
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Wer das Recht mit Füßen tritt, steht selten fest auf den Beinen. - Stanislaw Jerzy Lec
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!